期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 67, 期 1, 页码 56-60出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2010.01.001
关键词
Aspergillus; Caspofungin; Antifungal susceptibility testing
资金
- Astellas US (Deerfield, IL)
- Merck (Whitehouse Station, NJ)
- Pfizer Pharmaceuticals (New York, NY)
Antifungal susceptibility testing of Aspergillus spp. against caspofungin has been standardized by the Clinical and Laboratory Standards Institute (CLSI). Recent studies have documented breakthrough infections with Aspergillus spp. for which the minimum effective concentration (MEG) for caspofungin ranged from 0.25 to 8 mu g/mL. We tested a collection of 1590 clinical isolates of Aspergillus spp. (188 Aspergillus flavus, 1187 Aspergillus fumigatus, 114 Aspergillus niger, 71 Aspergillus terreus, and 30 Aspergillus versicolor) against caspofungin using the CLSI broth microdilution method. An epidemiologic cutoff value (ECV) of <= 0.06 mu g/mL encompassed the wild-type (WT) MEG distribution (percentage of MECs) of A. flavus (99.5%), A. fumigatus (98.7%), A. niger (100%), and A. terreus (97.2%), and an ECV of <= 0.12 mu g/mL encompassed the WT distribution of A. versicolor (96.7%). A total of 20 strains showed MECs that were outside the ECVs: 1 A. flavus (0.12 mu g/mL), 16 A. fumigatus (0.12 mu g/mL [13], 1 mu g/mL [1], 2 mu g/mL [2]), 2 A. terreus (0.12 [1] and >8 mu g/mL [1]), and 1 A. versicolor (4 mu g/mL). The establishment of the WT MEG distributions and ECVs for caspofungin and the major species of Aspergillus will be useful in resistance surveillance and is an important step toward the development of clinical breakpoints. (C) 2010 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据